Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

401 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.
Stelljes M, Beelen DW, Braess J, Sauerland MC, Heinecke A, Berning B, Kolb HJ, Holler E, Schwerdtfeger R, Arnold R, Spiekermann K, Müller-Tidow C, Serve HL, Silling G, Hiddemann W, Berdel WE, Büchner T, Kienast J; German AML Cooperative Group (AMLCG). Stelljes M, et al. Among authors: buchner t. Haematologica. 2011 Jul;96(7):972-9. doi: 10.3324/haematol.2011.041004. Epub 2011 Apr 1. Haematologica. 2011. PMID: 21459795 Free PMC article. Clinical Trial.
Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients.
Liersch R, Gerss J, Schliemann C, Bayer M, Schwöppe C, Biermann C, Appelmann I, Kessler T, Löwenberg B, Büchner T, Hiddemann W, Müller-Tidow C, Berdel WE, Mesters R. Liersch R, et al. Among authors: buchner t. Blood. 2012 May 31;119(22):5215-20. doi: 10.1182/blood-2011-11-389692. Epub 2012 Apr 17. Blood. 2012. PMID: 22510874 Free article. Clinical Trial.
Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center.
Pohlen M, Marx J, Mellmann A, Becker K, Mesters RM, Mikesch JH, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Krug U, Stelljes M, Karch H, Peters G, Gerth HU, Görlich D, Berdel WE. Pohlen M, et al. Among authors: buchner t. Haematologica. 2016 Oct;101(10):1208-1215. doi: 10.3324/haematol.2016.147934. Epub 2016 Jul 28. Haematologica. 2016. PMID: 27470601 Free PMC article.
Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.
Padró T, Bieker R, Ruiz S, Steins M, Retzlaff S, Bürger H, Büchner T, Kessler T, Herrera F, Kienast J, Müller-Tidow C, Serve H, Berdel WE, Mesters RM. Padró T, et al. Among authors: buchner t. Leukemia. 2002 Jul;16(7):1302-10. doi: 10.1038/sj.leu.2402534. Leukemia. 2002. PMID: 12094254 Clinical Trial.
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A; German AML Cooperative Group. Büchner T, et al. J Clin Oncol. 2003 Dec 15;21(24):4496-504. doi: 10.1200/JCO.2003.02.133. J Clin Oncol. 2003. PMID: 14673036 Clinical Trial.
401 results